Revelation Biosciences annual return on equity
2020
2021
2022
2023
2024
2025
Revelation Biosciences Return on Equity (ROE) Growth & History (REVB)
Revelation Biosciences's return on equity was −131.38% for fiscal 2025.
View full Revelation Biosciences company overviewRevelation Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −131.38% | +133.48 pp |
| 2024 | 2024-12-31 | −264.85% | −261.73 pp |
| 2023 | 2023-12-31 | −3.12% | +2269.65 pp |
| 2022 | 2022-12-31 | −2,272.77% | −1548.96 pp |
| 2021 | 2021-12-31 | −723.81% | −628.12 pp |
| 2020 | 2020-12-31 | −95.69% | — |
Revelation Biosciences quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −28.83% | +44.07 pp |
| Q1 2026 | 2026-03-31 | −27.54% | +26.51 pp |
| Q4 2025 | 2025-12-31 | −25.28% | +21.47 pp |
| Q3 2025 | 2025-09-30 | −25.72% | +91.82 pp |
| Q2 2025 | 2025-06-30 | −72.90% | +85.20 pp |
| Q1 2025 | 2025-03-31 | −54.05% | −20.79 pp |
| Q4 2024 | 2024-12-31 | −46.75% | −18.27 pp |
| Q3 2024 | 2024-09-30 | −117.54% | −91.56 pp |
| Q2 2024 | 2024-06-30 | −158.10% | −144.58 pp |
| Q1 2024 | 2024-03-31 | −33.27% | −144.54 pp |
| Q4 2023 | 2023-12-31 | −28.49% | +45.14 pp |
| Q3 2023 | 2023-09-30 | −25.98% | +582.72 pp |
| Q2 2023 | 2023-06-30 | −13.51% | — |
| Q1 2023 | 2023-03-31 | 111.28% | — |
| Q4 2022 | 2022-12-31 | −73.63% | +143.52 pp |
| Q3 2022 | 2022-09-30 | −608.70% | −549.14 pp |
| Q4 2021 | 2021-12-31 | −217.15% | −122.42 pp |
| Q3 2021 | 2021-09-30 | −59.56% | −40.64 pp |
| Q2 2021 | 2021-06-30 | −31.92% | — |
| Q1 2021 | 2021-03-31 | −42.41% | — |
| Q4 2020 | 2020-12-31 | −94.73% | — |
| Q3 2020 | 2020-09-30 | −18.92% | — |
Revelation Biosciences return on equity trends
Over the last five fiscal years, Revelation Biosciences's return on equity decreased from −95.69% to −131.38%, a change of −35.69 percentage points. The latest reported quarter, Q2 2026, shows −28.83%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Revelation Biosciences source filings ↗